Anti-tumor necrosis factor (anti-TNF) agents work to inhibit the tumor necrosis factor-alpha (TNF-a), which is one of the main proteins to cause the inflammation found in IBD.
- Humira, from AbbVie, has FDA approval to treat UC for adults, and to treat moderate to severe CD for those 6 years and older. Dosing varies with Humira, an anti-TNF agent, which is delivered through a subcutaneous (SC) injection.
- Remicade, which is also an anti-TNF agent, uses an intravenous (IV) delivery system administered by a health care professional. A patient’s physician determines the dosing. This therapy from Janssen treats those with UC and CD from 6 years old.
- Simponi, another treatment from Janssen, is approved for adults with UC using an SC delivery. Initial doses generally start with a 200 mgs injection with 100 mg administered in the second week of treatment. After those two injections, patients then receive 100 mgs every four weeks.
- Cimzia, an SC treatment from UCB, treats adults with CD. A patient receives a 400 mg starter dose, with that same dosage administered every four weeks thereafter.